| Literature DB >> 25054348 |
Shashank Gupta1, Pradeep Kumar Bhaskar1, Ritu Bhardwaj2, Abhishek Chandra3, Vidya Nair Chaudhry4, Prashaant Chaudhry4, Akhtar Ali5, Ashim Mukherjee1, Mousumi Mutsuddi1.
Abstract
Hyperhomocysteinemia induced by the C677T genetic variant in MTHFR (methylenetetrahydrofolate reductase) has been implicated in neuronal cell death of retinal ganglion cells (RGC), which is a characteristic feature of glaucoma. However, association of MTHFR C677T with glaucoma has been controversial because of inconsistent results across association studies. Association between MTHFR C677T and glaucoma has not been reported in Indian population. Therefore, with a focus on neurodegenerative death of RGC in glaucoma, the current study aimed to investigate association of MTHFR C677T with Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG) in a North Indian population. A total of 404 participants (231 patients and 173 controls) were included in this study. Genotyping was performed by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism. A few random samples were also tested by direct sequencing. Genotypic and allelic distributions of the POAG and PACG cohorts were compared to that of controls by chi-square test and odds ratios were reported with 95% confidence intervals. Genotypic and allelic distributions between POAG cases and controls were significantly different (p = 0.03 and p = 0.01 respectively). Unlike POAG, we did not find significant difference in the genotypic and allelic distributions of C677T between PACG cases and controls (p>0.05). We also observed a higher proportion of TT associated POAG in females than that in males. However, this is a preliminary indication of gender specific risk of C677T that needs to be replicated in a larger cohort of males and females. The present investigation on MTHFR C677T and glaucoma reveals that the TT genotype and T allele of this polymorphism are significant risk factors for POAG but not for PACG in North Indian population. Ours is the first report demonstrating association of MTHFR C677T with POAG but not PACG in individuals from North India.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25054348 PMCID: PMC4108368 DOI: 10.1371/journal.pone.0103063
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic Features of the Study Participants.
| Number of the Participants | Mean Age of the Participants | Female Participants and Mean Age | Male Participants and Mean Age | ||||||||
| POAG Cases | PACG Cases | Controls | POAG Cases | PACG Cases | Controls | POAG Cases | PACG Cases | Controls | POAG Cases | PACG Cases | Controls |
| 144 | 87 | 173 | 59.04±10.40 years | 56.31±9.13 years | 60.75±9.55 years | 46 (58.78±11.9 years) | 40 (56.4±8.75 years) | 96 (59.3±8.61 years) | 98 (59.16±9.68 years) | 47 (56.23±9.53 years) | 77 (62.5±10.39 years) |
Figure 1Genotyping of MTHFR C677T by PCR-RFLP.
Substitution of cytosine (C) by thymine (T) at MTHFR C677T creates a restriction site for HinfI (5′G/ANTC3′), therefore the PCR product with CC genotype remains undigested and appears as a 146 bp band on a 4% agarose gel. The CT genotype allows the 146 bp amplicon to be digested into two fragments of 124 bp and 22 bp, and hence produces three fragments of 146 bp, 124 bp and 22 bp. However, the 4% gel cannot resolve the 22 bp fragment and only the two higher bands are visible. A single band of 124 bp is inferred as TT genotype [28]. M: 100 bp DNA Ladder (NEB).
Figure 2Genotyping of MTHFR C677T by PCR-Sanger Sequencing.
Sequencing chromatograms depicting the three genotypes of MTHFR C677T. The SNP positions are shown by black arrows. (A) Homozygous wild type CC (B) Heterozygous CT (C) Homozygous mutant TT.
Distribution of MTHFR C677T in POAG Cases and Controls.
| Genotypic distribution | |||||
| Genotype | POAG Cases (144) | Control (173) | p (χ2) | Odds Ratio (OR) | 95% Confidence Interval (CI) |
|
| 101 (70.14%) | 137 (79.19%) | 0.03 (6.46) | ||
|
| 35 (24.30%) | 34 (19.65%) | |||
|
| 8 (5.56%) | 2 (1.16%) | |||
| Additive Model (TT vs. CC) | 0.01 (5.49) | 4.5 | 1.2–16.2 | ||
| Dominant Model (CT+TT vs. CC) | 0.06 (3.44) | 1.6 | 0.9–2.6 | ||
| Recessive Model (TT vs. CT+CC) | 0.02 (4.97) | 4.2 | 1.1–14.8 | ||
Gender-wise Comparison of POAG Cases and Controls.
| Females with POAG vs. Control Females | ||||
| Genotype | Females with POAG (46) | Control Females (96) | p (χ2) | OR (CI) |
| CC | 31 (67.39%) | 81 (84.38%) | 0.01 (9.18) | |
| CT | 10 (21.74%) | 14 (14.58%) | ||
| TT | 05 (10.87%) | 01 (1.04%) | ||
| Additive Model (TT vs. CC) | 0.003 (8.32) | 13.5 (2.2–79.7) | ||
| Dominant Model (CT+TT vs. CC) | 0.02 (5.38) | 2.7 (1.1–6.4) | ||
| Recessive Model (TT vs. CT+CC) | 0.006 (7.42) | 11.1 (1.9–63.5) | ||
Comparative Genotypic Distribution of MTHFR C677T in Females and Males with POAG.
| Genotype | Females (46) | Males (98) | p (χ2) | OR (CI) |
| CC | 31 (67.39%) | 70 (71.43%) | 0.15 (3.69) | |
| CT | 10 (21.74%) | 25 (25.51%) | ||
| TT | 05 (10.87%) | 03 (3.06%) | ||
| Additive Model (TT vs. CC) | 0.06 (3.39) | 4.1 (0.9–19.0) | ||
| Dominant Model (CT+TT vs. CC) | 0.62 (0.24) | 1.2 (0.5–2.5) | ||
| Recessive Model (TT vs. CT+CC) | 0.05 (3.63) | 4.3 (0.9–20.1) | ||
Distribution of MTHFR C677T in PACG Cases and Control.
| Genotypic Distribution | |||||
| Genotype | PACG Cases (87) | Control (173) | p (χ2) | Odds Ratio (OR) | 95% Confidence Interval (CI) |
| CC | 73 (83.91%) | 137 (79.19%) | 0.45 (1.56) | ||
| CT | 14 (16.09%) | 34 (19.65%) | |||
| TT | 0 (0%) | 2 (1.16%) | |||
| Additive Model (TT vs. CC) | 0.30 (1.06) | 0.21 | 0.01–4.0 | ||
| Dominant Model (CT+TT vs. CC) | 0.36 (0.82) | 0.73 | 0.3–1.4 | ||
| Recessive Model (TT vs. CT+CC) | 0.31 (1.01) | 0.22 | 0.01–4.1 | ||
Gender-wise Comparison of PACG Cases and Control.
| Females with PACG vs. Control Females | |||
| Genotype | Females with PACG (40) | Control Females (96) | p (χ2) |
| CC | 32 (80%) | 81 (84.38%) | 0.60 (0.99) |
| CT | 8 (20%) | 14 (14.58%) | |
| TT | 0 (0%) | 01 (1.04%) | |
Comparative Genotypic Distribution of MTHFR C677T in Females and Males with PACG.
| Genotype | Females (40) | Males (47) | p (χ2) |
| CC | 32 (80%) | 41 (87.23%) | 0.35 (0.83) |
| CT | 8 (20%) | 6 (12.77%) | |
| TT | 0 (0%) | 0 (0%) |